[go: up one dir, main page]

SG160430A1 - Immune modulators, preparations and compositions including immune modulators, tests for evaluating the activity of immune modulators and preparations and compositions including the same, and methods - Google Patents

Immune modulators, preparations and compositions including immune modulators, tests for evaluating the activity of immune modulators and preparations and compositions including the same, and methods

Info

Publication number
SG160430A1
SG160430A1 SG201001981-8A SG2010019818A SG160430A1 SG 160430 A1 SG160430 A1 SG 160430A1 SG 2010019818 A SG2010019818 A SG 2010019818A SG 160430 A1 SG160430 A1 SG 160430A1
Authority
SG
Singapore
Prior art keywords
immune modulators
preparations
compositions
compositions including
immune
Prior art date
Application number
SG201001981-8A
Other languages
English (en)
Inventor
David Lisonbee
Calvin W Mccausland
Richard H Bennett
Brent M Vaughan
Shane M Lefler
Original Assignee
4Life Res Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 4Life Res Llc filed Critical 4Life Res Llc
Publication of SG160430A1 publication Critical patent/SG160430A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/20—Milk; Whey; Colostrum
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/57—Birds; Materials from birds, e.g. eggs, feathers, egg white, egg yolk or endothelium corneum gigeriae galli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70514—CD4

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Urology & Nephrology (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
SG201001981-8A 2006-09-29 2007-09-19 Immune modulators, preparations and compositions including immune modulators, tests for evaluating the activity of immune modulators and preparations and compositions including the same, and methods SG160430A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84834806P 2006-09-29 2006-09-29
US11/855,944 US10471100B2 (en) 2006-09-29 2007-09-14 Nanofraction immune modulators, preparations and compositions including the same, and associated methods

Publications (1)

Publication Number Publication Date
SG160430A1 true SG160430A1 (en) 2010-04-29

Family

ID=39261440

Family Applications (1)

Application Number Title Priority Date Filing Date
SG201001981-8A SG160430A1 (en) 2006-09-29 2007-09-19 Immune modulators, preparations and compositions including immune modulators, tests for evaluating the activity of immune modulators and preparations and compositions including the same, and methods

Country Status (15)

Country Link
US (2) US10471100B2 (es)
EP (1) EP2068913B1 (es)
JP (3) JP5592651B2 (es)
CN (1) CN101553247B (es)
AU (1) AU2007305076B2 (es)
CO (1) CO6220833A2 (es)
EC (1) ECSP099296A (es)
ES (1) ES2658107T3 (es)
HK (1) HK1138181A1 (es)
MX (1) MX2009003324A (es)
MY (2) MY158857A (es)
RU (2) RU2518341C2 (es)
SG (1) SG160430A1 (es)
TW (1) TWI449530B (es)
WO (1) WO2008042604A2 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11197894B2 (en) 2006-09-29 2021-12-14 4Life Patents, Llc Nanofraction immune modulators, preparations and compositions including the same, and associated methods

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6866868B1 (en) * 2003-09-15 2005-03-15 4Life Research, Lc Compositions including different types of transfer factor, methods for making the compositions, and methods of treatment using the compositions
AU2006242106B2 (en) 2005-05-02 2013-01-17 4Life Patents, Llc Transfer factor preparations and associated methods
US9028882B2 (en) 2005-05-02 2015-05-12 4Life Patents, Llc Nutraceutical gels
WO2010129713A2 (en) * 2009-05-05 2010-11-11 4Life Patents, Llc Methods and systems for assaying, maintaining, and enhancing the activity of the immune system of a subject
CN103533958B (zh) 2010-11-23 2015-07-08 潘瑟里克公司 用于在广谱、未分化或混合临床应用中治疗的组合物和方法
CN102172360B (zh) * 2011-02-17 2013-04-24 南京大学 一种牛初乳提取物及其提取方法和应用
WO2013039373A2 (es) * 2011-09-13 2013-03-21 Zepeda Lopez Hector Manuel Extracto dializado de leucocitos de origen bazo de tiburón, para la obtención de factor de transferencia potencializado, y método de extracción, comprobación y conteo del mismo
WO2013039374A2 (es) * 2011-09-15 2013-03-21 Zepeda Lopez Hector Manuel Método de extracción, comprobación y conteo de extracto dializado de leucocitos de origen bazo de tiburón, para la obtención de factor de transferencia potencializado, específicamente diseñado para su uso como tratamiento contra la enfermedad conocida como vitíligo
WO2013043032A2 (es) * 2011-09-19 2013-03-28 Zepeda Lopez Hector Manuel Extracto dializado de leucocitos de origen bazo de tiburón para la obtención de factor de transferencia potencializado, específicamente diseñado para su uso como inmunomodulador y método de extracción, comprobación y conteo del mismo
WO2013043033A2 (es) * 2011-09-19 2013-03-28 Zepeda Lopez Hector Manuel Método de extracción, comprobacíon de extracto dializado de leucocitos de origen bazo de tiburón, para la obtención de factor de transferecia potencializado, específicamente diseñado para su uso como adyuvante potencializador de vacunas virales
WO2013058640A2 (es) * 2011-10-20 2013-04-25 Zepeda Lopez Hector Manuel Método de extracción, comprobación y conteo de extracto dializado de leucocitos de origen bazo de tiburón, para la obtención de factor de transferencia potencializado, específicamente diseñado para su uso como tratamiento contra la enfermedad conocida como asma
MX338863B (es) * 2011-12-16 2016-05-01 Inst Politecnico Nacional Metodo de obtencion de extracto dializable de leucocitos.
WO2015054694A2 (en) 2013-10-13 2015-04-16 4Life Patents, Llc Therapeutic compositions and methods for addressing physiological stresses and aging
KR101597540B1 (ko) * 2014-01-22 2016-02-29 건국대학교 산학협력단 난황 추출물을 유효성분으로 함유하는 면역증강용 조성물
US11578371B2 (en) 2017-06-15 2023-02-14 Mira Dx, Inc. Biomarkers for predicting tumor response to and toxicity of immunotherapy
US10933097B1 (en) 2020-03-05 2021-03-02 King Saud University Method of treating a bacterial infection using colostrum

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4402938A (en) * 1980-05-29 1983-09-06 Impro Products, Inc. Food and the method of extracting the same from colostrum and milk
JPS60208919A (ja) * 1983-11-25 1985-10-21 アムトロン・インコ−ポレイテツド トランスフア−フアクタ−を初乳から得る方法、こうして得られたトランスフア−フアクタ−及びその使用
US4816563A (en) 1983-11-25 1989-03-28 Amtron, Inc. Process for obtaining transfer factor from colostrum, transfer factor so obtained and use thereof
US5585098A (en) 1993-11-23 1996-12-17 Ovimmune, Inc. Oral administration of chicken yolk immunoglobulins to lower somatic cell count in the milk of lactating ruminants
CA2248792C (en) 1996-03-26 2008-01-08 Biotechnology Transfer, Inc. Methods for measurement of lymphocyte function
EP0904090B1 (en) 1996-03-26 2007-01-03 Arkion Life Sciences LLC Egg anti-inflammatory composition, method of isolation and use
US7169571B2 (en) 1997-09-12 2007-01-30 Cylex, Inc. Methods for measurement of lymphocyte function
CZ287956B6 (cs) * 1997-11-04 2001-03-14 Medipharm Cz, S. R. O. Perorální přípravek k prevenci a léčbě parvovirózy psů
US20020044942A1 (en) 2000-09-18 2002-04-18 Chisolm Biological Laboratory, Llc Transfer factor composition and process for producing same
US6468534B1 (en) 2000-09-21 2002-10-22 4Life Research, Lc Methods for obtaining transfer factor from avian sources, compositions including avian-generated transfer factor, and methods of use
EP1333847A1 (en) 2000-11-08 2003-08-13 Lorus Therapeutics Inc. Combination preparation of a biological response modidier and an anticancer agent and uses thereof
US20030003117A1 (en) 2001-06-18 2003-01-02 Michael Marenick Hydrolyzed whole egg products & related methods
AU2003216227A1 (en) 2002-02-11 2003-09-04 Arkion Life Sciences Llc Purified cytokine inhibitory factor
US20040005327A1 (en) 2002-05-16 2004-01-08 Subramanian Iyer Immune T-cell stimulation
WO2004041071A2 (en) 2002-11-04 2004-05-21 4Life Research, Lc Compositions, systems, and methods for focusing a cell-mediated immune response
CN1460522A (zh) 2003-06-16 2003-12-10 郭占军 预防和治疗疾病的蛋黄抗体组合物及其制备方法
US6866868B1 (en) 2003-09-15 2005-03-15 4Life Research, Lc Compositions including different types of transfer factor, methods for making the compositions, and methods of treatment using the compositions
US10471100B2 (en) 2006-09-29 2019-11-12 4Life Patents, Llc Nanofraction immune modulators, preparations and compositions including the same, and associated methods
CN100502674C (zh) 2005-10-13 2009-06-24 复旦大学 一种牛初乳和香菇提取物组合物及其制备方法和用途

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11197894B2 (en) 2006-09-29 2021-12-14 4Life Patents, Llc Nanofraction immune modulators, preparations and compositions including the same, and associated methods

Also Published As

Publication number Publication date
EP2068913A4 (en) 2009-12-02
JP2010504988A (ja) 2010-02-18
US20080081076A1 (en) 2008-04-03
TWI449530B (zh) 2014-08-21
AU2007305076A1 (en) 2008-04-10
JP2016196491A (ja) 2016-11-24
RU2009116274A (ru) 2010-11-10
JP2014129413A (ja) 2014-07-10
RU2619555C2 (ru) 2017-05-16
US20200069737A1 (en) 2020-03-05
US10471100B2 (en) 2019-11-12
MY158857A (en) 2016-11-15
MX2009003324A (es) 2009-06-30
RU2014102562A (ru) 2015-08-20
RU2518341C2 (ru) 2014-06-10
CN101553247B (zh) 2015-08-19
MY188915A (en) 2022-01-13
JP6401744B2 (ja) 2018-10-10
ES2658107T3 (es) 2018-03-08
WO2008042604A2 (en) 2008-04-10
EP2068913B1 (en) 2017-11-01
JP5592651B2 (ja) 2014-09-17
WO2008042604A3 (en) 2008-11-06
US11197894B2 (en) 2021-12-14
TW200831116A (en) 2008-08-01
CO6220833A2 (es) 2010-11-19
CN101553247A (zh) 2009-10-07
ECSP099296A (es) 2010-02-26
EP2068913A2 (en) 2009-06-17
AU2007305076B2 (en) 2011-04-28
HK1138181A1 (zh) 2010-08-20

Similar Documents

Publication Publication Date Title
SG160430A1 (en) Immune modulators, preparations and compositions including immune modulators, tests for evaluating the activity of immune modulators and preparations and compositions including the same, and methods
WO2006101955A3 (en) Liquid coating compositions
EP4353247A3 (en) Fgf21 mutants and uses thereof
IL184749A0 (en) Anti-interferon gamma antibodies and pharmaceutical compositions containing the same
TN2011000161A1 (en) Fgf21 mutants and uses thereof
MY152721A (en) Fgf21 mutants and uses thereof
WO2007041511A3 (en) Hematopoietic progenitor kinase 1 for modulation of an immune response
AU2008326599A8 (en) Modulation of the immune response
EP2365750A4 (en) BENZOXAZOLE KINASE INHIBITORS AND METHOD FOR THEIR USE
ATE480223T1 (de) Kosmetische zusammensetzungen mit blockcopolymeren und entsprechendes system von dauerhaften kosmetikprodukten
WO2006060182A3 (en) HIGHLY BRANCHED HK PEPTIDES AS EFFECTIVE CARRIERS OF siRNA
MX2010006466A (es) Moleculas de union al receptor ox40 de humano.
BRPI0503828A (pt) formulações contendo pó, aquosas, lìquidas, não alcoólicas
WO2008073174A3 (en) Antimicrobial therapy
MX2010002028A (es) Metodos y composiciones para modular celulas t.
NZ596813A (en) Drug delivery systems
WO2006053010A3 (en) Use of antioxidants for gene modulation
WO2007041364A3 (en) Conjugates for modulating the immune tolerance
WO2009017719A3 (en) Modulators of ccr9 receptor and methods of use thereof
WO2008027855A3 (en) Compositions and methods for modulating mtor signaling
WO2007002093A3 (en) Ansamycin formulations and methods of use thereof
WO2003083057A3 (en) Adipocytes and uses thereof
WO2022170093A3 (en) Compositions and methods for treating with car cells
MX2009009178A (es) Bis-fosforatos de bazedoxifeno.
Zhang et al. Effect of overexpresssion of angiotensin converting enzyme 2 on ventricular remodeling in rats after myocardial infarction